| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:NHI 2
CAS:1269802-97-2
Purity:98% by HPLC Remarks:NHI-2 is a lactate dehydrogenase isoform inhibitor with IC50 value of 14.7 μM. It has anti-glycolytic activity against a variety of cancer cells.
|
|
| Product Name: | NHI 2 | | Synonyms: | NHI 2;Methyl 1-hydroxy-6-phenyl-4-(trifluoromethyl)-1H-indole-2-carboxylate;1H-Indole-2-carboxylic acid, 1-hydroxy-6-phenyl-4-(trifluoromethyl)-, methyl ester;NHI-2 >=98% (HPLC) | | CAS: | 1269802-97-2 | | MF: | C17H12F3NO3 | | MW: | 335.28 | | EINECS: | | | Product Categories: | | | Mol File: | 1269802-97-2.mol |  |
| | NHI 2 Chemical Properties |
| Boiling point | 495.7±55.0 °C(Predicted) | | density | 1.36±0.1 g/cm3(Predicted) | | storage temp. | -20° | | solubility | Soluble in DMSO (up to 25 mg/ml). | | form | solid | | pka | 10?+-.0.58(Predicted) | | color | Off-white | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month. |
| | NHI 2 Usage And Synthesis |
| Description | NHI 2 is an inhibitor of lactate dehydrogenase A (LDHA; IC50 = 14.7 μM). It is selective for LDHA over LDHB (IC50 = 55.8 μM). It inhibits lactate production in HeLa cells when used at concentrations of 100 and 200 μM. NHI 2 is cytotoxic to HeLa cells (IC50 = 33.4 μM). | | storage | Store at +4°C | | References | 1) Granchi?et al., (2013),?Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (MaI) scaffolds; Org. Biomol. Chem.,?11?6588
2) Maftouh?et al. (2014), Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia; Br. J. Cancer,?110?172
3) Granchi?et al. (2011),?Discovery of N-Hydroxyindole-based Inhibitors of Human Lactate Dehydrogenase Isoform A (LDH-A) as Starvation Agents against Cancer Cells; J. Med. Chem.,?54?1599
4) Allison?et al. (2014),?Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p-53-independent pathways; Oncogenesis,?3?e102
5) Lea?et al. (2016)?Inhibition of growth by combined treatment with inhibitors of Lactate Dehydrogenase and either Phenformin of Inhibitors of 6-Phosphofructo-2-kinase / Fructose-2,6-bisphosphatase 3; Anticancer Research,?36?1479 [Focus Biomolecules Citation] |
| | NHI 2 Preparation Products And Raw materials |
|